Third View Private Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Third View Private Wealth’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	+767	New	+$181K	0.03%	273

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Third View Private Wealth's LGND Position: Q2 2026 in Review

Third View Private Wealth opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 767 shares worth $242K. The stake represents 0.03% of the portfolio and ranks #273 among its holdings.

192 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Third View Private Wealth held 767 shares of Ligand Pharmaceuticals worth $242K as of Q2 2026.
Ligand Pharmaceuticals was a new Third View Private Wealth position in Q2 2026.
Ligand Pharmaceuticals made up 0.03% of Third View Private Wealth's portfolio in Q2 2026, its #273 holding.
192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Third View Private Wealth's 13F filing for Q2 2026, filed 27 Jul 2026.